(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Chronic Lymphocytic Lymphoma
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Chronic Lymphocytic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FENTANYL National Cancer Institute (NCI) | Phase 1 | CC |
Ketorolac Tromethamine National Cancer Institute (NCI) | Phase 1 | CC |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE National Cancer Institute (NCI) | Phase 1 | CC |
HYDROMORPHON National Cancer Institute (NCI) | Phase 1 | CC |
Mssm/Biir Hdc Vax-001 Icahn School of Medicine at Mount Sinai | Phase 1 | CC |
Magrolimab National Cancer Institute (NCI) | Phase 1 | C |
Same molecule, other indications
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →